Research Article

Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.

Paulo Ricardo Martins-Filho, PhD1,2,*, Lis Campos Ferreira, MD, MSc2,3, Luana Heimfarth, PhD4, Adriano Antunes de Souza Araújo, PhD2,5, Lucindo José Quintans-Júnior, PhD2,4

1 Investigative Pathology Laboratory, Federal University of Sergipe, Aracaju, Sergipe, Brazil
2 Health Sciences Graduate Program, Federal University of Sergipe, Aracaju, Sergipe, Brazil
3 Department of Medicine, Tiradentes University, Aracaju, Sergipe, Brazil
4 Laboratory of Neuroscience and Pharmacological Assays, Department of Physiology, Federal University of Sergipe, São Cristovão, Sergipe, Brazil
5 Laboratory of Pharmaceutical Assays and Toxicity, Department of Pharmacy, Federal University of Sergipe, São Cristovão, Sergipe, Brazil

A R T I C L E   I N F O

Article history:
Received 2 July 2021
Revised 17 August 2021
Accepted 17 August 2021
Available online 29 August 2021

Keywords:
Hydroxychloroquine
COVID-19
SARS-CoV-2

A B S T R A C T

Background: Hydroxychloroquine (HCQ) is an anti-malarial and immunomodulatory drug considered a potential candidate for drug repurposing in COVID-19 due to their in vitro antiviral activity against SARS-CoV-2. Despite the potential antiviral effects and anti-inflammatory profile, the results based on clinical studies are contradictory. Therefore, the quality of the decision-making process from meta-analyses summarizing the available evidence selecting studies with different designs and unblinded trials is limited. The aim of this study was to synthesize the best evidence on the efficacy and safety of HCQ as pre-and post-exposure prophylaxis and treatment of non-hospitalized and hospitalized patients with COVID-19.

Methods: Searches were performed in PubMed, Web of Science, Embase, Lilacs, the website ClinicalTrials.gov and the preprint server medRxiv from January 1, 2020 to May 17, 2021. The following elements were used to define eligibility criteria: (1) Population: individuals at high-risk of exposure to SARS-CoV-2 (pre-exposure), individuals who had close contact with a positive or probable case of COVID-19 (post-exposure), non-hospitalized patients with COVID-19 and hospitalized patients with COVID-19; (2) Intervention: HCQ; (3) Comparison: placebo; (4) Outcomes: incidence of SARS-CoV-2 infection, need for hospitalization, length of hospital stay, need for invasive mechanical ventilation (MV), death, and adverse events; and (5) Study type: blinded, placebo-controlled, randomized clinical trials (RCTs). Risk of bias was judged according to the Cochrane guidelines for RCTs. Treatment effects were reported as relative risk (RR) for dichotomous variables and mean difference (MD) for continuous variables with 95% confidence intervals (CI). We used either a fixed or random-effects model to pool the results of individual studies depending on the presence of heterogeneity. The GRADE system was used to evaluate the strength of evidence between use of HCQ and the outcomes of interest.

Findings: Fourteen blinded, placebo-controlled RCTs were included in this meta-analysis. Four trials (1942 patients: HCQ = 1271; placebo = 671) used HCQ as a prophylactic medication pre-exposure to COVID-19, two (1650 patients: HCQ = 821; placebo = 829) as a prophylactic medication post-exposure to COVID-19, three (1018 patients: HCQ = 497; placebo = 521) as treatment for non-hospitalized patients, and five (1138 patients: HCQ = 572; placebo = 566) as treatment for hospitalized patients with COVID-19. We found no decreased risk of SARS-CoV-2 infection among individuals receiving HCQ as pre-exposure
(RR = 0.90; 95% CI 0.46 to 1.77) or post-exposure (RR = 0.96; 95% CI 0.72 to 1.29) prophylaxis to prevent COVID-19. There was no significant decreased risk of hospitalization for outpatients with SARS-CoV-2 infection (RR = 0.64; 95% CI 0.33 to 1.23) and no decreased risk of MV (RR = 0.81; 95% CI 0.49 to 1.34) and death (RR = 1.05; 95% CI 0.62 to 1.78) among hospitalized patients with COVID-19 receiving HCQ. The certainty of the results on the lack of clinical benefit for HCQ was rated as moderate. Moreover, our results demonstrated an increased risk for any adverse events and gastrointestinal symptoms among those using HCQ.

**Interpretation:** Available evidence based on the results of blinded, placebo-controlled RCTs showed no clinical benefits of HCQ as pre- and post-exposure prophylaxis and treatment of non-hospitalized and hospitalized patients with COVID-19.

**Funding:** There was no funding source.
2. Methods

2.1. Search strategy

Searches were performed in PubMed, Web of Science, Embase, Lilacs, the website ClinicalTrials.gov and the preprint server medRxiv from January 1, 2020 to May 17, 2021. The search was limited to studies published in full-text versions, without language restriction. In the ClinicalTrials.gov, only completed studies with results were analyzed. The reference lists of all eligible studies and reviews were scanned to identify additional studies for inclusion. The structured search strategies used for each database with specific filters and grey-literature are detailed in the supplementary file.

2.2. Study selection and eligibility criteria

Two reviewers (P.R.M.-F. and L.C.F.) independently screened the search results and identified studies that were potentially relevant based on their title and abstract. Relevant studies were read in full and selected according to the eligibility criteria. Disagreements between the two reviewers were resolved by consensus.

The following elements were used to define eligibility criteria:

(1) Population: Individuals at high-risk of exposure to SARS-CoV-2 (pre-exposure), individuals who had close contact with a possible or probable case of COVID-19 (post-exposure), non-hospitalized patients with COVID-19 and hospitalized patients with COVID-19.

(2) Intervention: HCQ. Trials that tested drug associations were excluded.

(3) Comparison: Placebo.

(4) Outcomes:

- Pre- and post-exposure prophylaxis: incidence of SARS-CoV-2 infection and any adverse events.
- Non-hospitalized patients with COVID-19: need for hospitalization, death, and any adverse events.
- Hospitalized patients with COVID-19: length of hospital stay, need for invasive mechanical ventilation (MV), death, and any adverse events.

(5) Study type: blinded, placebo-controlled, RCTs. Eligible studies must report at least 1 of the outcomes of interest. Potential overlapping populations, open-label trials, and observational studies were excluded.

2.3. Data extraction

Two authors (P.R.M.-F. and L.C.F.) extracted the data from included studies and crosschecked them for accuracy. Using a standardized data extraction sheet, the following information were extracted from the studies: registry of study protocol, demographic characteristics of study participants, pre-existing medical conditions, treatment arms, HCQ protocol, concomitant medications, follow-up duration, and outcome data. We also extracted data on serious adverse events, QTc interval >500ms and other cardiac events, gastrointestinal symptoms (vomiting, diarrhea, and abdominal pain), skin reaction (rash), headache, and neurologic reactions (irritability, dizziness, vertigo, and seizures).

2.4. Risk of bias assessment

Risk of bias was judged according to the Cochrane guidelines for RCTs [13]. The following domains were evaluated: sequence generation and allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), trial discontinuation (early stopping bias), sample size calculation and power analysis (small sample bias), outcome measurements (information bias), and the authors’ financial or non-financial conflicts of interest that could possibly contaminate the judgment of the research team when designing, conducting, or reporting the study. Self-reported diagnosis of COVID-19 was classified as a high risk of information bias. Studies using real-time reverse transcription polymerase chain reaction (RT-PCR) to detect SARS-CoV-2 or, if testing was limited, provided a clinical diagnosis based on COVID-19-related symptoms and epidemiological data were considered as having a low risk of bias.

2.5. Data synthesis

Treatment effects were reported as relative risk (RR) for dichotomous variables (incidence of SARS-CoV-2 infection, need for hospitalization, need for MV, death, and adverse events) and mean difference (MD) for continuous variables (length of hospital stay) with 95% confidence intervals (CI). To calculate MD, means and standard deviations (SD) were obtained for each study group. If the means and SD were not directly reported in the publication, indirect methods of extracting estimates were used [14]. A negative mean difference indicated that HCQ was beneficial in reducing the length of stay for hospitalized patients with COVID-19. To calculate the RR, the number of events and individuals in each treatment group were extracted. For studies using three or more different dosages of HCQ, we combined all treatment groups to a single large group.

We used either a fixed or random-effects model to pool the results of individual studies depending on the presence of heterogeneity. Statistical heterogeneity was quantified by the I² index using the following interpretation: 0%, no between-study heterogeneity; <50%, low heterogeneity; 50–75%, moderate heterogeneity; >75%, high heterogeneity [15]. In the case of heterogeneity, we used the random-effects model, otherwise, the fixed-effects model was used. The results of the meta-analysis for each outcome were presented according to the population characteristics and therapeutic proposal (pre-exposure prophylaxis, post-exposure prophylaxis, treatment of non-hospitalized individuals and treatment of hospitalized individuals). We also provided an additional analysis on the overall risk for any and serious adverse events, QTc interval >500ms and other cardiac manifestations, gastrointestinal symptoms, skin rash, headache, and neurologic reactions for individuals receiving HCQ.

Although funnel plots may be useful tools in investigating small study effects in meta-analyses, they have limited power to detect such effects when there are few studies [16]. Therefore, because we had a small number of studies included according to the population characteristics and use of HCQ, we did not perform a funnel plot analysis. Forest plots were used to present the effect sizes and the 95% CI, and 2-tailed p < 0.05 was used to determine significance. Analyses were conducted using Review Manager, version 5.3 (Cochrane IMS).

2.6. Grading the strength of evidence

We graded the strength of evidence for the association between use of HCQ and the outcomes of interest as high, moderate, low, or very-low using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) rating system [17,18]. In the GRADE system, RCTs begin as high-quality evidence but may be downgraded according to the risk of bias assessment, inconsistency, indirectness, imprecision in the results, and publication bias [19]. Certainty is uprated for estimates with large (RR > 2.0 or RR < 0.5) or very-large (RR > 5.0 or RR < 0.2) magnitude of effect.
Quality of evidence was lowered when the proportion of information from studies at high risk of bias was sufficient to affect the interpretation of results. Evidence of inconsistency included important variations in point estimates, no overlapping of confidence intervals, inconsistency in direction of effect, and considerable between-study heterogeneity ($I^2 > 75\%$). Reasons of indirectness included differences in study populations and interventions, use of surrogate outcomes, and inadequate follow-up time. The width of CI for the pooled estimates and the optimal information size (OIS) were analyzed for imprecision [20]. OIS was calculated using the following formula [21]: $$\text{OIS} = \left(4 \left( Z_{1 - \alpha} + Z_{1 - \beta}\right)^2 \cdot P(1 - P)/\delta^2 \right) / (1/1 - P),$$ where $\alpha = 5\%$, $\beta = 80\%$, $P =$ control group risk, $\delta =$ difference between control group risk and intervention group risk, and $I^2 =$ between-study heterogeneity.

Although the funnel plot asymmetry was not evaluated, we reduced the potential for publication bias planning a comprehensive search including grey-literature without restrictions. In this criterion, we analyzed discrepancies in findings between peer-reviewed and non-peer reviewed publications and the influence of small trials ($< 100$ patients per arm) on estimated treatment effects. The influence of non-peer reviewed publications and small trials on the pooled estimates was analyzed using a “leave-one-out” sensitivity approach [22].

Role of the funding source

There is no funding source.

3. Results

Search strategy yielded 2871 potentially relevant records. After screening of titles and abstracts and evaluation of completed trials retrieved from ClinicalTrials.gov, 33 full-text articles were assessed for eligibility and 14 blinded, placebo-controlled RCTs [23–36] were included in the meta-analysis. No trials evaluating the efficacy and safety of CQ in COVID-19 were found. Of the included trials, four [33–36] used HCQ as a prophylactic medication pre-exposure to COVID-19, two [31,32] as a prophylactic medication post-exposure to COVID-19, three [28–30] as treatment for non-hospitalized patients, and five [23–27] as treatment for hospitalized patients with COVID-19. A flow diagram of the study selection process and specific reasons for exclusion are detailed in Figure 1.

3.1. HCQ as pre-exposure prophylaxis to prevent SARS-CoV-2 infection

Population included healthcare workers in the USA, Canada, Mexico, and Pakistan at high-risk of exposure to SARS-CoV-2. Tri-
als enrolled individuals with no history of SARS-CoV-2 infection and no symptoms suggestive of COVID-19. All trial protocols were registered on ClinicalTrials.gov, had a parallel design, and were classified as Phase 2 or Phase 3. Dosage regimens of HCQ were different between studies and outcomes were assessed up to 8 or 12 weeks (Table S1; supplementary file). Most studies had a low risk for selection, performance, detection, attrition, reporting, and information bias. One study was designed as a single blinded RCT and classified as having a high risk for detection bias [34]. Three trials stopped early [33,35,36] and there was potential for small sample bias in all studies (Figure S1; supplementary file).

The four blinded, placebo-controlled RCTs enrolled a total of 1942 healthcare workers, 1271 in the HCQ group and 671 in the placebo group. Individual results showed no clinical benefit on HCQ use as pre-exposure prophylaxis to prevent SARS-CoV-2 infection (Table S2; supplementary file). In the meta-analysis, we found no decreased risk of SARS-CoV-2 infection (RR = 0.90; 95% CI 0.46 to 1.77) and no increased risk for any adverse events (RR = 1.36; 95% CI 0.91 to 2.03) for healthcare workers receiving HCQ. The quality of evidence was graded as low for the outcomes of interest (Table 1) (Figures S2 and S3; supplementary file).

This meta-analysis included results of two peer-reviewed studies [33,36] and two studies published in grey-literature [34,35]. In the sensitivity analysis, peer-reviewed studies showed no decreased risk of SARS-CoV-2 infection (RR = 0.76; 95% CI 0.52 to 1.10) but an increased risk for any adverse events (RR = 1.60; 95% CI 1.33 to 1.92) among those using HCQ, and the certainty was graded as moderate and high, respectively. No effect on the use of HCQ was found summarizing the results from non-peer-reviewed publications and the quality of evidence was classified as very-low (Table S3; supplementary file).

### 3.2. HCQ as post-exposure prophylaxis to prevent SARS-CoV-2 infection

The studies were conducted in the USA and Canada and included adults who had close contact (occupational or household exposure) with a person with known SARS-CoV-2 infection within the prior 96 hours. During trial enrollment in both studies, eligible participants with symptoms consistent with COVID-19 were excluded. All trial protocols were registered on ClinicalTrials.gov, had a parallel design, and were classified as Phase 3. Dosage regimens of HCQ were different between studies and outcomes were assessed within 14 days (Table S4; supplementary file). Studies evaluating HCQ as post-exposure prophylaxis to prevent SARS-CoV-2 infection had a low risk for selection, performance, detection, attrition, reporting, and information bias. However, a high risk for early stopping bias and small sample bias was detected in both trials (Figure S4; supplementary file).

The two blinded, placebo-controlled RCTs enrolled a total of 1650 individuals, 821 in the HCQ group and 829 in the placebo group. Individual results showed no clinical benefit on HCQ use as post-exposure prophylaxis to prevent SARS-CoV-2 infection (Table S5; supplementary file). In the meta-analysis, we found no decreased risk of SARS-CoV-2 infection (RR = 0.96; 95% CI 0.72 to 1.29) among individuals receiving HCQ, but there was an increased risk for any adverse events within 14 days after trial enrollment (RR = 1.91; 95% CI 1.20 to 3.04). Included studies were peer-reviewed and the quality of evidence was graded as moderate.
Table 3  Evidence synthesis on the efficacy and safety of hydroxychloroquine as treatment for non-hospitalized patients with COVID-19.

| Outcomes | Number of patients | HCQ | Placebo | RR (95% CI) | p-value | I² | Quality of evidence |
|----------|--------------------|-----|---------|-------------|---------|----|---------------------|
| Hospitalizations | 14/497 (2.8%) | 23/521 (4.4%) | 0.64 (0.33 to 1.23) | 0.18 | 0% | ⬤⬤⬤⬤ * |  |
| Deaths | 1/497 (0.2%) | 2/521 (0.4%) | 0.62 (0.08 to 4.68) | 0.64 | 0% | ⬤⬤⬤⬤ * |  |
| Any adverse events | 143/490 (29.2%) | 97/514 (18.9%) | 1.43 (0.85 to 2.38) | 0.18 | 72% | ⬤⬤⬤⬤ ** |  |

HCQ, hydroxychloroquine. RR, relative risk. CI, confidence interval. Certainty: ⊘ very low; ⬤ low; ⬤⬤ moderate; ⬤⬤⬤⬤ high.

* Risk of bias: not serious; Inconsistency: not serious; Indirectness: not serious; Imprecision: serious; Discrepancies in findings between peer-reviewed and non-peer reviewed publications: not applicable; Influence of small trials (<100 patients per arm): no; Large effect: no.

** Risk of bias: not serious; Inconsistency: serious; Indirectness: not serious; Imprecision: serious; Discrepancies in findings between peer-reviewed and non-peer reviewed publications: not applicable; Influence of small trials (<100 patients per arm): no; Large effect: no.

3.3. HCQ as treatment for non-hospitalized patients with COVID-19

The studies were conducted in the USA, Canada and Brazil and included symptomatic, non-hospitalized adults with either laboratory-confirmed SARS-CoV-2 infection or COVID-19 compatible symptoms. All trial protocols were registered on ClinicalTrials.gov, had a parallel design, and were classified as Phase 3. Dosage regimens of HCQ were different between studies and outcomes were assessed between 14 and 90 days (Table S6; supplementary file). All studies evaluating HCQ as treatment of non-hospitalized patients with COVID-19 had a low risk for selection, performance, attrition, and information bias. There was an unclear risk for detection bias in the study by Johnston et al. [28] and a high risk for reporting bias in the study by Reis et al. [29] due to the differences in the evaluation time of primary outcomes between trial protocol (28 days) and full report (90 days). Two trials stopped early and were classified as having a high risk for small sample bias [28,29]. (Figure S7; supplementary file).

The three blinded, placebo-controlled RCTs enrolled a total of 1018 individuals, 497 in the HCQ group and 521 in the placebo group. Individual results showed no clinical benefit in HCQ use as treatment for non-hospitalized patients with COVID-19 (Table S7; supplementary file). In the meta-analysis, we found no reduced risk of hospitalization (RR = 0.64; 95% CI 0.33 to 1.23) and death (RR = 0.62; 95% CI 0.08 to 4.68) and no increased risk of any adverse events (RR = 1.43; 95% CI 0.85 to 2.38) among outpatients with COVID-19 receiving HCQ. Included studies were peer-reviewed and the quality of evidence was graded as moderate for hospitalization and death, and low for any adverse events (Table 3) (Figures S8 – S10; supplementary file).

3.4. HCQ as treatment for hospitalized patients with COVID-19

The studies were conducted in the USA, Mexico and France and included non-critically and critically ill patients with COVID-19 requiring hospitalization. All trial protocols were registered on ClinicalTrials.gov, had a parallel design, and were classified as Phase 2 or Phase 3. Dosage regimens of HCQ were similar in most studies and outcomes were assessed up to 14 and 28-30 days (Table S8; supplementary file). Most studies evaluating HCQ as treatment for hospitalized patients with COVID-19 had a low risk for selection, performance, detection, attrition, reporting, and information bias. There was potential risk for reporting bias in the study by Hernandez-Cardenas et al. [26] due to the difference in the evaluation time of primary outcomes between trial protocol (120 days) and full report (30 days). Four trials stopped early [23,24,26,27] and there was potential risk for small sample bias in all studies (Figure S11; supplementary file).

The five blinded, placebo-controlled RCTs enrolled a total of 1138 individuals, 572 in the HCQ group and 566 in the placebo group. Individual results showed no clinical benefit on HCQ use as treatment for hospitalized patients with COVID-19 (Table S9; supplementary file). In the meta-analysis, we found no difference in the length of hospital stay between patients treated with HCQ and placebo (MD = 1.20; 95% CI -0.32 to 2.72) (Figure 2). There was no decreased risk of mechanical ventilation [2 weeks] RR = 0.81; 95% CI 0.49 to 1.34; [4 weeks] RR = 0.97; 95% CI 0.52 to 1.80) and death ([2 weeks] RR = 1.05; 95% CI 0.62 to 1.78; [4 weeks] RR = 0.87; 95% CI 0.67 to 1.13) among hospitalized patients with COVID-19 receiving HCQ. No increased risk of any adverse events was found (RR = 1.07; 95% CI 0.89 to 1.29) (Table 4) (Figures S12 – S16; supplementary file).

All trials evaluating the need for mechanical ventilation and any adverse events were peer-reviewed as well as trials reporting data on deaths during two weeks of follow-up. Of the five trials reporting data on deaths during four weeks of follow-up, three were peer-reviewed [23,24,27] and two were non-peer reviewed publications [25,26]. The quality of evidence was graded as moderate for the outcomes of interest (Table 4). In the sensitivity analysis for mortality during four weeks of follow-up, we found no decreased risk for death from peer reviewed (RR = 0.88; 95% CI 0.58 to 1.33) and non-peer reviewed (RR = 0.80; 95% CI 0.42 to 1.55) publica-
tions, and the quality of evidence was also classified as moderate (Table S10; supplementary file).

3.5. Risk of any and serious adverse events, QTc interval >500ms and other cardiac events, gastrointestinal symptoms, headache, rash, and neurologic reactions for individuals using HCQ.

We found an increased risk for any adverse events (RR = 1.38; 95% CI 1.12 to 1.71) and gastrointestinal symptoms (RR = 2.45; 95% CI 1.77 to 3.39) among individuals treated with HCQ. However, there was no increased risk for serious adverse events (RR = 1.07; 95% CI 0.69 to 1.67), QTc >500ms (RR = 2.13; 95% CI 0.96 to 4.71) and other cardiac manifestations (RR = 1.52; 95% CI 0.60 to 3.83), headache (RR = 0.93; 95% CI 0.55 to 1.56), skin rash (RR = 1.46; 95% CI 0.89 to 2.29), and neurologic reactions (RR = 1.20; 95% CI 0.80 to 1.78) (Table 5) (Figures S17 – S24; supplementary file).

4. Discussion

There is still no optimal approach for COVID-19 management and the repurposing potential of several drugs, including remdesivir, ivermectin, chloroquine, favipiravir, lopinavir-ritonavir, ribavirin, interferon, CQ and HCQ, have been tested for prevention and treatment of this disease. Despite drug repurposing played a critical role in the identification of rapidly available therapeutic solutions against SARS-CoV-2 infection [37], to date, only remdesivir and tocilizumab were approved by the US Food and Drug Administration (FDA) and other health agencies for the treatment of hospitalized patients with COVID-19. The evidence for suggesting repurposing HCQ is based on observations of decreased viral replication in vitro [1] but results from clinical data are contrasting. 23–36

In this systematic review and meta-analysis, we synthesized the available evidence on the efficacy and safety of HCQ for the prevention and treatment of COVID-19 based on the results of blinded, placebo-controlled RCTs. Our findings confirm the inefficacy of HCQ against COVID-19 in the current state of the art as established by best practices.

HCQ, a 4-aminoquinoline compound used as an antimalarial drug, was reported to be effective at inhibiting SARS-CoV-2 infection in vitro due to the intracellular pH change and interference with the glycosylation of ACE2 receptor and the spike protein leading to blockade of virus entry into target cells [1]. Despite promising preclinical results, HCQ has not been shown effective as pre- and post-exposure prophylaxis to COVID-19, and the National Institutes of Health (NIH) [38], WHO [11] and the European Medical Agency (EMA) [39] have not recommend the use of any drug as prophylaxis against SARS-CoV-2 infection, except in clinical trials. The use of general prevention measures such as

---

### Table 4
Evidence synthesis on the efficacy and safety of hydroxychloroquine as treatment for hospitalized patients with COVID-19.

| Outcomes                        | Number of patients | RR (95% CI) | p-value | I² |
|---------------------------------|--------------------|-------------|---------|----|
| **Mechanical ventilation**      |                    |             |         |    |
| 2 weeks                         | 26/433 (6.0%)      | 0.81 (0.49 to 1.34) | 0.42 | 0% |
| 4 weeks                         | 19/433 (4.4%)      | 0.97 (0.52 to 1.80) | 0.91 | 0% |
| **Death**                       |                    |             |         |    |
| 2 weeks                         | 27/433 (6.2%)      | 1.05 (0.62 to 1.78) | 0.86 | 0% |
| 4 weeks                         | 80/572 (14.0%)     | 0.87 (0.67 to 1.13) | 0.30 | 0% |
| **Any adverse events**          | 122/433 (28.2%)    | 1.07 (0.89 to 1.29) | 0.45 | 0% |

HCQ, hydroxychloroquine. RR, relative risk. CI, confidence interval.

Certainty: @ very-low; @@ low; @@@ moderate; @@@@@ high.

- Risk of bias: not serious; Inconsistency: not serious; Imprecision: serious; Discrepancies in findings between peer-reviewed and non-peer reviewed publications:
- no / not applicable; Influence of small trials (<100 patients per arm): no; Large effect: no.

---

### Table 5
Evidence synthesis on the safety of hydroxychloroquine for COVID-19 based on the results of blinded, placebo-controlled, randomized clinical trials.

| Adverse events                  | Number of patients | RR (95% CI) | p-value | I² |
|---------------------------------|--------------------|-------------|---------|----|
| **Any adverse events**          | 857/2896 (29.6%)   | 1.38 (1.12 to 1.71) | -0.01 | 76% |
| **Serious adverse events**      | 38/1047 (3.6%)     | 1.07 (0.69 to 1.67) | 0.76 | 0% |
| **QTc interval >500ms**         | 18/359 (5.0%)      | 2.13 (0.96 to 4.71) | 0.06 | 0% |
| **Other cardiac manifestations**| 58/706 (8.2%)      | 1.52 (0.60 to 3.83) | 0.37 | 64% |
| **Gastrointestinal symptoms**   | 371/2222 (16.7%)   | 2.45 (1.77 to 3.39) | -0.01 | 58% |
| **Headache**                    | 33/1357 (2.4%)     | 0.93 (0.55 to 1.56) | 0.79 | 7% |
| **Skin rash**                   | 37/1528 (2.4%)     | 1.46 (0.89 to 2.39) | 0.13 | 0% |
| **Neurologic reactions**        | 49/1461 (3.4%)     | 1.20 (0.80 to 1.78) | 0.38 | 0% |

HCQ, hydroxychloroquine. RR, relative risk. CI, confidence interval.
mask wearing, hand hygiene, and physical distancing remain indicated and are effective nonpharmacologic interventions to reduce the spread of this infection [40,41]. In addition, vaccines currently available have shown 50%-95% effectiveness in preventing COVID-19 [42–47]. Therefore, mass vaccination presents as the most cost-effective measure for controlling and preventing SARS-CoV-2 infection.

Currently, there is a consensus that symptomatic cases of COVID-19 require supportive care with medical evaluation, stratification of risk factors for worse clinical outcomes [48–50], clinical monitoring of symptoms, and complementary exams if indicated. Measures to reduce the risk of SARS-CoV-2 transmission as patient isolation should also be considered. In outpatients, symptomatic treatment includes analgesics and antipyretics. For patients with dyspnea, prone positioning and respiratory physiotherapy may be indicated [51,52]. Regular fluid intake should also be advised to avoid dehydration, and walking should be encouraged respecting patient’s tolerance. SARS-CoV-2 specific monoclonal antibodies (bamlanivimab, bamlanivimab with etesevimab, and casirivimab with imdevimab) have been considered in the treatment of outpatients with mild to moderate COVID-19, in the presence of high-risk criteria [53–58]. In clinical trials, HCQ has not been associated with a reduction in the prevalence, severity, or duration of COVID-19 symptoms [28–30], and there is no decreased risk of hospitalization for outpatients with SARS-CoV-2 infection treated with the drug. Patients treated with HCQ in clinical trials have achieved HCQ concentrations lower than target values identified in in vitro assays [33]. However, in vivo antiviral efficacy of HCQ may be possible only if the in vivo concentration is sufficiently high, which can lead to increased risk of systemic exposure, adverse events, and toxicity [59]. Although we have included two trials [30,31] using HCQ dosing regimen designed to achieve and maintain drug concentration above half the estimated maximum effective concentration (EC50) for SARS-CoV-2, individual results showed no effect of HCQ in the prevention or treatment of outpatients with COVID-19, but an increased risk of adverse drug events.

Patients with persistent dyspnea, chest pain, hypoxia with a measured oxygen saturation below 94%, altered mental status, or persistent fever should be evaluated for the need of hospital admission. Although a SARS-CoV-2 specific drug has not been identified yet, management protocols and a few medications have shown a positive impact on patient outcomes. For example, supplemental oxygen and prone position when necessary, and adequate management of pulmonary ventilation are widely adopted protocols for COVID-19 hospitalized patients [60–63]. Extracorporeal membrane oxygenation has been indicated in severe refractory cases [64–67]. For some patients, SARS-CoV-2 infection may lead to a massive release of proinflammatory cytokines and hypercoagulable state increasing the risk for thromboembolic events [68–70]. Management of those events with low molecular weight heparin (LMWH) or unfractionated heparin has been decided on a case-by-case basis [71].

In hospitalized patients with COVID-19, dexamethasone was shown to reduce mortality in patients who required supplemental oxygen [72]. Remdesivir, an FDA-approved intravenous antiviral drug, has been associated in double-blinded, placebo-controlled RCTs with a faster time to clinical improvement in severe cases of COVID-19, but results on mortality are contrasting [73,74]. Recently, there is emerging evidence on the efficacy of tocilizumab, an interleukin-6 inhibitor, on clinical outcomes in critical COVID-19 patients with systemic inflammation and rapid respiratory deterioration [75,76]. In hospital setting, our results found no difference in the length of stay and no decreased risk for mechanical ventilation and deaths among patients treated with HCQ compared to placebo.

Evidence of the efficacy of HCQ for COVID-19 provided by previous systematic reviews and meta-analyses are conflicting, which is expected when studies with different designs are summarized. The combination of results from studies with different study designs, dissimilarity, methodological weaknesses, and high degree of inconsistency into a single meta-model can lead to biased results. In a living systematic review [77] using evidence from RCTs, cohort studies, and case series, it was found that HCQ can improve pulmonary CT findings with low-quality of evidence, but there is no effect on mortality, need for mechanical ventilation, progression to severe disease, symptom resolution, and upper respiratory viral clearance. Other meta-analyses [9,10] have also shown that HCQ is more likely to be associated with the observation of favourable clinical outcomes including symptoms duration and death. However, recent research [78,79] pooling results from open-label and blinded clinical trials have indicated trivial to no effect of HCQ on hospitalization and mortality. The present high-quality meta-analysis using comparable studies strengthens the evidence on the inefficacy of HCQ in different clinical settings and provides important information for healthcare decision makers.

In addition to not having found clinical benefits of HCQ to prevent or treat COVID-19, our results demonstrated an increased risk for any adverse events and gastrointestinal symptoms among those using HCQ. Although a higher proportion of individuals treated with HCQ had QTc interval > 500ms compared to placebo (5.0% vs. 2.2%), there is no statistical difference between groups and no cases of arrhythmia or death associated to HCQ were reported. However, we must consider the fact that patients at higher risk of cardiotoxicity were excluded from these studies and the indiscriminate use of these drugs should be avoided.

5. Limitations

Our results had limitations and included trials stopped early and with high risk for small sample bias. In addition, we found an important influence of non-peer reviewed studies in the quality of evidence for some outcomes of interest. However, the certainty of the results on the lack of clinical benefit for HCQ was rated as moderate and we believe that the true effect is probably close to the estimated effect. Finally, we did not investigate the dose-response relationship of HCQ and potential adverse events.

6. Conclusion

Available evidence based on the results of blinded, placebo-controlled RCTs showed no clinical benefits of HCQ as pre-and post-exposure prophylaxis and treatment of non-hospitalized and hospitalized patients with COVID-19.

Contributors

PRMF: conceptualisation, methodology, project administration, supervision, study selection, data extraction, data analysis, risk of bias assessment, and writing. LCF: study selection, data extraction, risk of bias assessment, and writing. LH, LQJ and AASA: methodology, literature search, and writing. All authors discussed the results and contributed to the final manuscript.

Declaration of interests

The authors declare that there is no conflict of interest.

Data sharing statement

The data sets used and analyzed during the current study are available from the corresponding author upon reasonable request.
high-risk outpatient adults: A randomized clinical trial. Clinical Medicine 2021;33:10077.
[29] Rese G, Moreira Silva EA dos S, Medeiros Silva DC, et al. Effect of Early Treat-
ment With Hydroxychloroquine and Remdesivir on Risk of Hospital-
ization Among Patients With COVID-19. JAMA Netw Open 2021;4:e2126468.
[30] Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospital-
ized Adults With Early COVID-19. Ann Intern Med 2020;173:623–31.
[31] Bagnoli DR, Pullen Y, Villalba AS, et al. A Randomized Trial of Hydroxy-
chloroquine as Postexposure Prophylaxis for COVID-19. N Engl J Med 2020;
383:517–25.
[32] Karnabas R, ER Brown, Bershineyn A, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Respiratory Syndrome Coronavirus 2 Infection, Ann Intern Med 2021;174:344–52.
[33] Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as Pre-
exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Work-
er. A Randomized Controlled Trial. Clin Infect Dis 2021;72:935–43.
[34] Syed F, Arif MA, Niazi R, et al. Pre-Exposure Prophylaxis with Various Doses of Hydroxychloroquine among high-risk COVID 19 Healthcare Personnel: CHEER randomized controlled trial. medRxiv 2021.
[35] Rojas-Serrano J, Thirion-Romero AMFJ, Vazquez-Perez J, Ramirez-Venez-
gas FM-NA, Perez-Kawabe KM, Perez-Padilla R. For Proph-
ophylaxis Of COVID-19 In Health Workers: A Randomized Clinical Trial. medRxiv 2021.
[36] Abella BS, Jolokovsky EL, Binyt FT, et al. Efficacy and Safety of Hydroxychloro-
quine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. JAMA Intern Med 2021;181:195–202.
[37] Martinez MA. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treat-
ment. Front Immunol 2021;12:553711.
[38] NIH. Prevention and Prophylaxis of SARS-CoV-2 Infection. https://www.
covid19treatmentguidelines.nih.gov/overview/prevention-of-sars-cov-2. 2021.
[39] EMA. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes, 2021. https://www.ema.
europa.eu/en/news/chloroquine-hydroxychloroquine-only-be-used-clinical-trials-
emergency-use-programmes. 2020.
[40] Chu DK, Ald EA, Duda S, et al. Physical distancing, face masks, and eye protec-
tion to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 2020;395:1973–87.
[41] Brooks JT, Butler JC. Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2. JAMA 2021;325:998–9.
[42] Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFIHCOV Study. SSRN Electronic Journal.
[43] Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inac-
ivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:803–12.
[44] Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the Cha-
dox1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111.
[45] Baden LR, el Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403–16.
[46] Polack FP, Thomas JS, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2003–15.
[47] Saifudd S, Gray G, Vazquez A, et al. Safety and Efficacy of Single-Dose Ad26.Cov2.S Vaccine against Covid-19. N Engl J Med 2021;384:2187–201.
[48] Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021;93:1449–59.
[49] Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and labor-
atory data. Eur J Intern Med 2020;76:36–41.
[50] Martins-Filho PR, Antunes de Souza Acara R, Pereira LX, et al. Factors Associ-
ated with Mortality Among Hospitalized Patients with COVID-19: A Retrospec-
tive Cohort Study. Am J Prev Med Hyg 2021;104:103–5.
[51] Jagan N, Morrow LE, Walters RW, et al. The POSITIONED Study: Prone Pos-
ing in Nonventilated Coronavirus Disease 2019 Patients—A Retrospect-
tive Analysis. Crit Care Explor 2020;2:e00229.
[52] Touchon F, Trigui Y, Prud’homme E, et al. Awake prone positioning for hy-
porenic respiratory failure: past, COVID-19 and perspectives. Eur Respir Rev 2021;30:210022.
[53] US Food and Drug Administration. Fact sheet for health care providers emerg-
ency use authorization (EUA) of bamlanivimab and etesevimab. https://www.
fda.gov/media/145802/download.
[54] US Food and Drug Administration. Fact sheet for health care providers emerg-
ency use authorization (EUA) of bamlanivimab. https://www.fda.gov/media/143630/download.
2020.
[55] Regeneron Pharmaceuticals IncFact sheet for health care providers: emergency use authorization (EUA) of casirivimab and imdevimab. Regeneron 2020 https://www.regeneron.com/sites/default/files/treatment-covid19-eua-fact-
sheet-for-hcp.pdf.
[56] Gill RB, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Mod-
erate COVID-19. JAMA 2021;325:632–44.
[57] Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody EC055 in Outpatients with Covid-19. N Engl J Med 2021;384:229–37.
[58] Taylor PC, Adams AC, Hufford MM, de la Torre L, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 2021;21:382–93.

[59] Fan J, Zhang X, Liu J, et al. Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019. Clin Infect Dis 2020;71:3232–6.

[60] Avdeev SN, Yaroshetsky AI, Tsareva NA, et al. Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19. Am J Emerg Med 2021;39:154–7.

[61] Grieco DL, Menga LS, Cesarano M, et al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure. JAMA 2021;325:1731–43.

[62] Botta M, Tsiosas AM, Pillay J, et al. Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (ProVENT-COVID): a national, multicentre, observational cohort study. Lancet Respir Med 2021;9:139–48.

[63] Damanti S, Ramirez GA, Bozzolo EP, et al. 6-Month Respiratory Outcomes and Exercise Capacity of COVID-19 Acute Respiratory Failure Patients Treated with CPAP. Intern Med J 2021 published online May 7.

[64] Badulak J, Antonini MV, Stead CM, et al. Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization, ASAIO J 2021;67:485–95.

[65] Lebreton G, Schmidt M, Ponnaiah M, et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. Lancet Respir Med 2021;9:213–20.e1(21) e00965-5.

[66] Saeed O, Tatooles AJ, Farooq M, et al. Characteristics and outcomes of patients with COVID-19 supported by extracorporeal membrane oxygenation: A retrospective multicenter study. J Thorac Cardiovasc Surg 2021;S0022-5223(21) 00861-1.

[67] Lorusso R, Combes A, Lo Coco V, et al. ECMO for COVID-19 patients in Europe and Israel. Intensive Care Med 2021;47:344–8.

[68] Lodigiani C, Lapichino G, Careno L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020;191:9–14.

[69] Helms J, Tacquard C, Severe C, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089–98.

[70] Abou-Ismail MY, Diamond A, Kapoor S, Afzah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020;194:101–15.

[71] Soeiro A de M, Leal T de CAT, Pereira M de P, et al. Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19) - 2020. Arq Bras Cardiol 2020;115:292–301.

[72] Collaborative Group RECOVERY. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693–704.

[73] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569–78.

[74] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med 2020;383:1813–1826.

[75] Collaborative Group RECOVERY. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:1637–45.

[76] The REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021;384:1491–1502.

[77] Hernandez AV, Roman YM, Pasapuleti V, et al. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Intern Med 2020;173:287–96.

[78] Kashour Z, Kashour T, Gerber D, Tleyjeh IM. Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Clin Transl Sci 2021;14:1101–12.